Toll-like receptor adaptor molecule 1 (TRIF)

Toll-like receptor adaptor molecule 1 (TRIF), also known as TICAM-1, is a critical adapter protein in the innate immune system that mediates the MyD88-independent signaling pathway for Toll-like receptors 3 (TLR3) and 4 (TLR4) [UniProt: Q8IWT1]. Upon activation by ligands such as double-stranded RNA or lipopolysaccharide, TRIF recruits downstream signaling molecules like TRAF3 and TBK1, leading to the activation of interferon regulatory factor 3 (IRF3) and the subsequent production of Type I interferons and pro-inflammatory cytokines [PubMed: 12855817]. This pathway is essential for antiviral defense, the maturation of dendritic cells, and the regulation of cell death processes including apoptosis and necroptosis [PubMed: 24037352]. Dysregulation of TRIF signaling is implicated in various pathologies, including chronic inflammatory diseases, autoimmune disorders, and a heightened susceptibility to viral infections, most notably herpes simplex encephalitis [PubMed: 17848655]. In drug development, the TRIF pathway is targeted by TLR3 and TLR4 agonists to enhance vaccine responses and cancer immunotherapy, while inhibitors are being investigated to treat excessive inflammation in conditions like sepsis and autoimmunity [PubMed: 29343438].

Other names

TICAM-1TICAM1PRIC285Toll-interleukin-1 receptor domain-containing adapter protein inducing interferon-beta

Modulation of the TRIF-dependent pathway via TLR3 or TLR4 agonism or antagonism to regulate the production of Type I interferons and pro-inflammatory cytokines.